Invivyd faces a significant regulatory hurdle after the Food and Drug Administration moved to terminate the emergency use authorization for Pemgarda, its Covid-19 prevention medication. The designation is scheduled to expire on June 29 of next year, putting immediate pressure on the company's product pipeline.

Meanwhile, London-based Clarivate saw its shares drop following the announcement of a $600 million divestiture. The provider of analytics and workflow solutions is selling its life-science and healthcare arm to New York-based investment firm Altaris. Clarivate leadership stated the exit is designed to sharpen the company's focus on AI-driven intelligence tools tailored for academic, government, and intellectual-property markets.